HeartBeam is moving ahead with a limited market launch of its portable ECG platform following recent regulatory clearance, as the company works to expand remote cardiac monitoring options beyond traditional clinical settings.

The Santa Clara, California-based company develops cardiac monitoring technology intended to capture clinically relevant electrocardiogram data outside hospitals or physician offices. Its system centers on a handheld device that records cardiac electrical signals and synthesizes them into a 12-lead ECG, a format typically produced only in clinical environments.

HeartBeam received FDA clearance in December 2025 for software that converts signals captured by its device into a synthesized 12-lead ECG used for arrhythmia assessment. The company plans a limited commercial rollout of the technology in early 2026.
The HeartBeam System records signals from three directions using embedded electrodes built into a credit card–sized device. The signals are processed through a personalized transformation matrix to generate a 12-lead ECG. The cable-free design allows patients to record cardiac activity during symptoms such as palpitations or irregular heart rhythms without visiting a healthcare facility.

Conventional 12-lead ECG systems typically require multiple wired electrodes and trained staff, limiting their use to clinics and hospitals. Portable consumer ECG devices, meanwhile, often rely on single-lead recordings that provide less detailed information for clinical evaluation. HeartBeam’s platform is designed to combine portability with higher-resolution data typically associated with clinical systems.

The company is also developing additional hardware, including a prototype extended-wear patch monitor capable of generating synthesized 12-lead ECG data over longer monitoring periods. Extended cardiac monitoring represents a large and established market with reimbursement pathways.

Beyond hardware, HeartBeam is building analytical software to interpret the data generated by its system. The company is developing artificial intelligence tools designed to compare patient recordings with baseline ECG data and flag clinically meaningful changes. Future FDA submissions are planned for these algorithms.

HeartBeam is also pursuing regulatory clearance for an indication related to heart attack detection. According to the U.S. Centers for Disease Control and Prevention, heart disease remains the leading cause of death in the United States, accounting for roughly one in five deaths annually.

The company’s broader strategy focuses on enabling patients to capture clinically useful ECG data when symptoms occur, with clinicians reviewing results remotely as part of expanding telehealth and remote monitoring programs.

U.S. Healthcare Homepage